针对T细胞淋巴瘤的个性化免疫疗法:从免疫逃脱到精确治疗方法
Joshua M L Casan1,2,3, Xiao Jing Ong1,3, Carrie van der Weyden1,2
1The Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne, VIC 3010, Australia.
尽管免疫疗法取得了进展,但外围T细胞淋巴瘤 (PTCL) 的结果不佳. 针对免疫逃生机制和使用生物标志物进行个性化治疗的新策略为PTCLs精密治疗提供了希望.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 外围T细胞淋巴瘤 (PTCL) 由于生物异质性和化疗耐药性,预后不佳.
- 了解PTCL的免疫基因组和微环境基础,揭示了各种免疫逃生机制.
研究的目的:
- 审查关于PTCL免疫失调和免疫治疗进展的当前文献.
- 在PTCL中概述新型免疫治疗策略的生物学理由.
- 讨论针对个性化PTCL治疗的生物标志物驱动方法.
主要方法:
- 关于PTCL免疫基因组学和微环境的文献综合.
- 审查新兴的免疫治疗策略 (例如检查点抑制剂,CAR-T细胞).
- 对生物标志物发现的分子,转录和微环境分析进行讨论.
主要成果:
- 通过抗原呈现缺陷,亡,粘附和瘤微环境重塑,PTCLs表现出免疫逃逸.
- 新型免疫疗法显示出令人鼓舞但不一致的活性,需要个性化的方法.
- 生物标志物驱动的分层对于提高PTCL治疗效率至关重要.
结论:
- 深入了解PTCL生物学支持新的免疫治疗策略.
- 通过剖析发现生物标志物,使得适应性试验设计和精准医学成为可能.
- 未来的PTCL疗法旨在超越经验主义,转向量身定制,有效的治疗方法.
更多相关视频
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
